Expert Opinion on Therapeutic Targets最新文献_第10页

Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments. 心脏传导疾病：了解分子机制，发现未来治疗目标。

IF 4.6 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-05-01 Epub Date: 2024-05-13 DOI: 10.1080/14728222.2024.2351501

Tingting Li, Qussay Marashly, Jitae A Kim, Na Li, Mihail G Chelu

{"title":"Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments.","authors":"Tingting Li, Qussay Marashly, Jitae A Kim, Na Li, Mihail G Chelu","doi":"10.1080/14728222.2024.2351501","DOIUrl":"10.1080/14728222.2024.2351501","url":null,"abstract":"Introduction: The cardiac conduction system (CCS) is crucial for maintaining adequate cardiac frequency at rest and modulation during exercise. Furthermore, the atrioventricular node and His-Purkinje system are essential for maintaining atrioventricular and interventricular synchrony and consequently maintaining an adequate cardiac output.Areas covered: In this review article, we examine the anatomy, physiology, and pathophysiology of the CCS. We then discuss in detail the most common genetic mutations and the molecular mechanisms of cardiac conduction disease (CCD) and provide our perspectives on future research and therapeutic opportunities in this field.Expert opinion: Significant advancement has been made in understanding the molecular mechanisms of CCD, including the recognition of the heterogeneous signaling at the subcellular levels of sinoatrial node, the involvement of inflammatory and autoimmune mechanisms, and the potential impact of epigenetic regulations on CCD. However, the current treatment of CCD manifested as bradycardia still relies primarily on cardiovascular implantable electronic devices (CIEDs). On the other hand, an If specific inhibitor was developed to treat inappropriate sinus tachycardia and sinus tachycardia in heart failure patients with reduced ejection fraction. More work is needed to translate current knowledge into pharmacologic or genetic interventions for the management of CCDs.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"385-400"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11395937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand? 动脉粥样硬化中降脂和抗炎疗法的新目标和作用机制：该领域的现状如何？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-05-01 Epub Date: 2024-06-04 DOI: 10.1080/14728222.2024.2362644

Stephen J Nicholls, Adam J Nelson

{"title":"New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?","authors":"Stephen J Nicholls, Adam J Nelson","doi":"10.1080/14728222.2024.2362644","DOIUrl":"10.1080/14728222.2024.2362644","url":null,"abstract":"Introduction: Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality worldwide, despite widespread use of statins. There is a need to develop additional therapeutic strategies that will complement statins to achieve more effective reductions in cardiovascular risk.Areas covered: This review provides a comprehensive summary of current areas of therapeutic development targeting both lipid and inflammatory factors implicated in the pathogenesis of atherosclerosis. In addition to develop of novel approaches that will produce more effective lowering of low-density lipoprotein cholesterol, clinical trials are currently evaluating the potential to target other atherogenic lipid parameters such as triglyceride-rich lipoproteins and Lp(a), in addition to promoting the biological properties of high-density lipoproteins. Targeting inflammation within the vascular wall has emerged as a new frontier in cardiovascular prevention, with early evidence that use of anti-inflammatory agents have the potential to reduce cardiovascular risk.Expert opinion: Clinical practice has an increasing array of therapeutic tools to achieve more effective lowering of low-density lipoprotein cholesterol for high-risk patients. In addition, clinical trials have the potential to deliver a range of additional agents to the clinic, that target alternative lipid and inflammatory mediators. This will permit the potential to personalize cardiovascular prevention.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"375-384"},"PeriodicalIF":5.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

S100A1: a promising therapeutic target for heart failure S100A1：有望治疗心力衰竭的靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-19 DOI: 10.1080/14728222.2024.2345746

Dorothea Noll, Dorothea Kehr, Patrick Most, Julia Ritterhoff

引用次数: 0

Molecular drilling to combat salmonella typhi biofilm using L-Asparaginase via multiple targeting process 利用 L-天冬酰胺酶通过多重靶向过程对抗伤寒沙门氏菌生物膜的分子钻研

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-19 DOI: 10.1080/14728222.2024.2344699

Aditya Upadhyay, Dharm Pal, Awanish Kumar

引用次数: 0

Role of Non-receptor tyrosine kinases in epilepsy: significance and potential as therapeutic targets 非受体酪氨酸激酶在癫痫中的作用：作为治疗靶点的意义和潜力

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-17 DOI: 10.1080/14728222.2024.2343952

Ozasvi R Shanker, Sonali Kumar, Jyotirmoy Banerjee, Manjari Tripathi, P Sarat Chandra, Aparna Banerjee Dixit

引用次数: 0

Promising therapeutic targets for the treatment of urine storage dysfunction: what’s the status? 治疗尿储藏功能障碍的有望治疗靶点：现状如何？

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-17 DOI: 10.1080/14728222.2024.2344698

Karl-Erik Andersson

引用次数: 0

Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus 抗抑郁作用的增效：NPY1R 激动剂和氯胺酮协同作用可增强腹侧海马的 TrkB 信号转导和神经发生

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-16 DOI: 10.1080/14728222.2024.2342524

Carlos Arrabal-Gómez, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Natalia Garcia-Casares, Kjell Fuxe, Dasiel Borroto-Escuela, Manuel Narváez

引用次数: 0

Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for Major depressive disorder 通过长期共同激活加拉宁 2 (GALR2) 和神经肽 Y1 受体 (NPY1R)，提高神经元存活率和 BDNF：重度抑郁障碍的潜在治疗靶点

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-15 DOI: 10.1080/14728222.2024.2342517

Dasiel Borroto-Escuela, Pedro Serrano-Castro, Jose Andrés Sánchez-Pérez, Miguel Angel Barbancho-Fernández, Kjell Fuxe, Manuel Narváez

引用次数: 0

An update on the development on tubulin inhibitors for the treatment of solid tumors 治疗实体瘤的微管蛋白抑制剂的最新进展

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-04-15 DOI: 10.1080/14728222.2024.2341630

Prasanna Anjaneyulu Yakkalaa, Shaik Rahaman, P.S. Lakshmi Soukya, Sajeli Ahil Begum, A Kamal

引用次数: 0

Guillain-Barré syndrome: immunopathogenesis and therapeutic targets. 格林-巴利综合征：免疫发病机制和治疗目标。

IF 5.8 2区医学

Expert Opinion on Therapeutic Targets Pub Date : 2024-03-01 Epub Date: 2024-03-18 DOI: 10.1080/14728222.2024.2330435

Shan Liu, Wei Wei Zhang, Linpei Jia, Hong-Liang Zhang

{"title":"Guillain-Barré syndrome: immunopathogenesis and therapeutic targets.","authors":"Shan Liu, Wei Wei Zhang, Linpei Jia, Hong-Liang Zhang","doi":"10.1080/14728222.2024.2330435","DOIUrl":"10.1080/14728222.2024.2330435","url":null,"abstract":"Introduction: Guillain-Barré syndrome (GBS) is a group of acute immune-mediated disorders in the peripheral nervous system. Both infectious and noninfectious factors are associated with GBS, which may act as triggers of autoimmune responses leading to neural damage and dysfunction.Areas covered: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccines as well as flaviviruses have been associated with GBS, although a robust conclusion has yet to be reached. Immunomodulatory treatments, including intravenous immunoglobulins (IVIg) and plasma exchange (PE), have long been the first-line therapies for GBS. Depending on GBS subtype and severity at initial presentation, the efficacy of IVIg and PE can be variable. Several new therapies showing benefits to experimental animals merit further investigation before translation into clinical practice. We review the state-of-the-art knowledge on the immunopathogenesis of GBS in the context of coronavirus disease 2019 (COVID-19). Immunomodulatory therapies in GBS, including IVIg, PE, corticosteroids, and potential therapies, are summarized.Expert opinion: The association with SARS-CoV-2 remains uncertain, with geographical differences that are difficult to explain. Evidence and guidelines are lacking for the decision-making of initiating immunomodulatory therapies in mildly affected patients or patients with regional subtypes of GBS.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"131-143"},"PeriodicalIF":5.8,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0